You are here
- Boston Biomedical-Columbia University Oncology Strategic Alliance: Request for Proposals
Boston Biomedical-Columbia University Oncology Strategic Alliance: Request for Proposals
This strategic research alliance is a collaboration between Boston Biomedical, a wholly owned subsidiary of Sumitomo Pharma in Japan, and Columbia University, to advance research toward the development of disruptive technology platforms, novel science, and IND ready molecule(s) in the field of oncology.
Areas of Interest:
Novel therapeutics and platform technologies with a focus on Oncology including (but not limited to):
- Cancer Genomics and Epigenomics
- Tumor biology and microenvironment
- Precision Oncology and Systems Biology
- Cancer Population Science
- Cancer cell metabolism
- Immune-oncology and immunotherapy
- Gene and cell therapy
- DNA vaccines and therapy
- RNAi and oncolytic viruses
- Drug delivery systems
- Gene editing
- Mechanisms of anti-aging therapy
- Imaging and radio-omics
Applicants must have a full-time Columbia University faculty appointment.
Short Proposal Submission Process:
Applicants should prepare a 3 page non-confidential short proposal using the Boston Biomedical – Columbia University RFP proposal submission template. The deadline for submission of short proposals is December 4th, 2019.
Review Process and Selection of Final Award Recipients:
Boston Biomedical will review the non-confidential Short Proposals and determine further interest in the development of a confidential Full Proposal. Full Proposals will be written by the applicants in collaboration with Boston Biomedical’s R&D leadership.
Wednesday, December 4, 2019: Deadline for submission of non-confidential short proposals
Early January 2020: Announcement of proposals advanced to submission of Full Proposals
January - February 2020: Development of Full Proposals in collaboration with Boston Biomedical
March 2020: Project Initiation
For more information:
Please contact [email protected]
Please submit non-confidential short proposals: